Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix

Ecosphere Technologies, Inc. (OTCBB: ESPH) said Monday that it delivered two more Ozonix EF80 units to Hydrozonix LLC as part of a long-term contract with water treatment solutions company. Hydrozonix is a strategic alliance of a consortium of the principals at Phillips and Jordan, Inc., the Siboney Group and PBA Holdings that provides mobile, eco-friendly water treatment solutions to the oil and gas exploration and production industry.

Stuart, Florida-based Ecosphere’s Ozonix products utilize patented, non-chemical oxidation technologies to eliminate liquid chemicals from wastewater treatment operations. A single Ozonix oxidation system can process up to 3,300 gallons of water per minute; treating the polluted water to levels suitable for re-use.

The latest two units bring the total units delivered to Hydrozonix to 12. Ecosphere is now working on production of the next two units for delivery, according to today’s corporate statement. The last two units were delivered in the third quarter.

Since delivery of the first unit in September 2011, Hydrozonix has treated about 19 million barrels (nearly 800 million gallons) of water with the Ozonix EF80 units, enabling 100 percent recycling of flowback and produced waters.

“Hydrozonix now has a fleet of Ozonix EF80 units that are being deployed in a variety of shale plays throughout the U.S. to continue to extend the reach of our patented Ozonix technology,” commented John Brewster, Chairman and chief executive at Ecosphere.

In November, the Ecosphere reported third-quarter revenue of $7.3 million, broken down into $6.2 million in equipment sales and $1.1 million in field service sales. Gross profit totaled $2.5 million. Net income for the quarter was $300,000, marking the third consecutive profitable quarter for the company.

In the first nine months of 2012, revenues from equipment and licensing equaled $17.6 million, a 212 percent improvement of the same period in 2011. Field service revenue in the nine months through September slid by 7 percent to $6.7 million compared to the year prior period. Gross profit in the nine months was $9.3 million, a 56% increase over the year prior timeframe. Net income totaled $1.2 million, or 1 cent per common share. The quarter ended with the company having $3.7 million in cash on hand.

Shares of have soared in 2013 so far. After hitting 32 cents each in December, a steady rise to today’s trading price of 49 cents has followed, representing a 53 percent appreciation in value.

Ecosphere Technologies (ESPH) Stock Quote and News:

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

	Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0) By Rex Graham A Glaxo Smith Kline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vical, Inc. (VICL), and Sanofi Pasteur (SNY) offer new hope for an effective vaccine treatment. A Yale University study published in the Nov. 15, 2012,

	Senate Approves Tax Hikes and Delay in Spending Cuts(0) Technically, the United States has gone over the fiscal cliff with January 1 arriving before a new budget was passed to avert a series of automatic tax increases and deep spending cuts. But, the Senate said Tuesday morning that the White House and Senate Republicans have come to terms to raise taxes on households bringing-in

	ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0) Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013. Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement. Previously, Smith spent ten

	Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0) Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announced that it has entered into a common stock purchase agreement

	Drinks Americas Signs Sales Agreement for Marigold Craft Beer(0) Alcoholic beverage maker Drinks Americas Holdings, Ltd. (OTCBB: DKAM) said Thursday that is has penned an exclusive sales agreement with Marigold Brewing Company to bring a new line of craft brewery beer to the United States. Marigold will be the first line of micro-brewed beer made in Mexico and sold in the States, according to

Stay Informed

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.